Flawless clinical profiles cannot salvage a drug from manufacturing facility failures.
Even when therapeutic candidates demonstrate stellar clinical safety and efficacy, the FDA will block approval based entirely on quality control and facility deficiencies at manufacturing partners.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Sobi's novel gout combination drug was denied approval on the basis of contract manufacturing and facility control deficiencies rather than clinical failure.
Achieve Life Sciences' clinically robust smoking cessation drug was blocked by an FDA rejection triggered entirely by facility deficiencies at its manufacturing partner.
The FDA issued a Complete Response Letter rejecting the drug entirely due to third-party facility and manufacturing compliance issues, despite acceptable clinical safety and efficacy.
A highly effective liver cancer therapy remains blocked in the U.S. due to persistent compliance and facility deficiencies at its manufacturing sites.
Unicycive's therapy faced a second FDA rejection solely due to unresolved partner manufacturing issues, with no safety or efficacy concerns raised.